Press Release No. 20
Berlin
Drug candidate based on MDC patent submitted for FDA approval
At the end of last year, Baxter International Inc. announced that the company has submitted a biologics license application to the United States (US) Food and Drug Administration (FDA) for the approval of BAX111, a recombinant von Willebrand factor (rVWF) in development for the treatment of patients with von Willebrand disease, the most common type of inherited bleeding disorder. The candidate received orphan-drug designation from both the European Commission and the FDA.